• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Rates of opioid agonist treatment prescribing in provincial prisons in Ontario, Canada, 2015-2018: a repeated cross-sectional analysis
Conclusions The increase in opioid agonist treatment prescribing between 2015 and 2018 in provincial prisons shows that efforts to scale up access to treatment in the context of the opioid overdose crisis have included people who experience incarceration in Ontario. Further work is needed to understand unmet need for treatment and treatment impacts.
Source: BMJ Open - November 18, 2021 Category: General Medicine Authors: Bodkin, C., Bondy, S., Regenstreif, L., Kiefer, L., Kouyoumdjian, F. Tags: Open access, Addiction Source Type: research

Facilitators of and barriers to buprenorphine initiation for people with opioid use disorder in the emergency department: protocol for a scoping review
Introduction Buprenorphine–naloxone is recommended as a first-line agent for the treatment of opioid use disorder. Although initiation of buprenorphine in the emergency department (ED) is evidence based, barriers to implementation persist. A comprehensive review and critical analysis of both facilitators of and barriers to buprenorphine initiation in ED has yet to be published. Our objectives are (1) to map the implementation of buprenorphine induction pathway literature and synthesise what we know about buprenorphine pathways in EDs and (2) to identify gaps in this literature with respect to barriers and facilitator...
Source: BMJ Open - September 27, 2021 Category: General Medicine Authors: Bozinoff, N., Soobiah, C., Rodak, T., Bucago, C., Kingston, K., Klaiman, M., Poynter, B., Samuels, G., Schoenfeld, E., Shelton, D., Kalocsai, C. Tags: Open access, Addiction Source Type: research

Observational study of the safety of buprenorphine+naloxone in pregnancy in a rural and remote population
Conclusions Retrospective data suggest that there likely is no harm from taking buprenorphine+naloxone opioid agonist treatment in pregnancy. Larger, prospective studies are needed to further assess safety.
Source: BMJ Open - October 30, 2016 Category: Journals (General) Authors: Jumah, N. A., Edwards, C., Balfour-Boehm, J., Loewen, K., Dooley, J., Gerber Finn, L., Kelly, L. Tags: Open access, Addiction, Medical management, Paediatrics, Public health, Obgyn Research Source Type: research

The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales
Conclusions Our analysis of the relative safety of buprenorphine and methadone for opioid substitution treatment reveals that buprenorphine is six times safer than methadone with regard to overdose risk among the general population. Clinicians should be aware of the increased risk of prescribing methadone, and tighter regulations are needed to prevent its diversion.
Source: BMJ Open - May 29, 2015 Category: Journals (General) Authors: Marteau, D., McDonald, R., Patel, K. Tags: Open access, Addiction, Evidence based practice, Medical management, Public health Research Source Type: research